Antidepressant action of ketamine via mTOR is mediated by inhibition of nitrergic Rheb degradation

Molecular Psychiatry
M M HarrazSolomon H Snyder

Abstract

As traditional antidepressants act only after weeks/months, the discovery that ketamine, an antagonist of glutamate/N-methyl-D-aspartate (NMDA) receptors, elicits antidepressant actions in hours has been transformative. Its mechanism of action has been elusive, though enhanced mammalian target of rapamycin (mTOR) signaling is a major feature. We report a novel signaling pathway wherein NMDA receptor activation stimulates generation of nitric oxide (NO), which S-nitrosylates glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Nitrosylated GAPDH complexes with the ubiquitin-E3-ligase Siah1 and Rheb, a small G protein that activates mTOR. Siah1 degrades Rheb leading to reduced mTOR signaling, while ketamine, conversely, stabilizes Rheb that enhances mTOR signaling. Drugs selectively targeting components of this pathway may offer novel approaches to the treatment of depression.

Associated Clinical Trials

References

Mar 1, 1991·Journal of Neurochemistry·J J Vornov, J T Coyle
Feb 25, 2000·Biological Psychiatry·R M BermanJ H Krystal
Jan 4, 2001·Naunyn-Schmiedeberg's Archives of Pharmacology·P C WaldmeierB Hengerer
Jul 28, 2004·Molecular Psychiatry·D C Javitt
May 11, 2005·Journal of Neurobiology·Michael A Sutton, Erin M Schuman
May 14, 2005·Neuroscience and Biobehavioral Reviews·Stephanie C Dulawa, Rene Hen
Jan 5, 2006·The American Journal of Psychiatry·Carlos A ZarateDennis S Charney
Mar 1, 2006·Proceedings of the National Academy of Sciences of the United States of America·Makoto R HaraSolomon H Snyder
Aug 9, 2006·Archives of General Psychiatry·Carlos A ZarateHusseini K Manji
Dec 20, 2007·The European Journal of Neuroscience·Per SvenningssonPaul Greengard
Jun 17, 2008·Nature Cell Biology·Nilkantha SenAkira Sawa
Dec 19, 2009·Neuropharmacology·Herbert E CovingtonEric J Nestler
Aug 20, 2010·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Peng XiaStuart A Lipton
Oct 26, 2010·Nature Cell Biology·Jonathan S Stamler, Douglas T Hess
Dec 8, 2010·Neuro-Signals·Nikolaus J SucherFrances E Jensen
Dec 8, 2010·Nature Medicine·James W Murrough, Dennis S Charney
Nov 30, 2011·Proceedings of the National Academy of Sciences of the United States of America·Nilkantha Sen, Solomon H Snyder
Mar 5, 2013·Biological Psychiatry·Andrzej PilcPhil Skolnick
Aug 29, 2013·The American Journal of Psychiatry·James W MurroughSanjay J Mathew
Jun 10, 2014·Proceedings of the National Academy of Sciences of the United States of America·Erinn S GideonsLisa M Monteggia
Aug 6, 2014·European Journal of Pharmacology·Olivia F O'LearyJohn F Cryan
Jan 7, 2015·Current Opinion in Neurobiology·Lisa M Monteggia, Carlos Zarate

❮ Previous
Next ❯

Citations

Oct 6, 2016·BJPsych Open·Gin S MalhiMauricio Tohen
Jul 14, 2016·Expert Opinion on Drug Discovery·Agnieszka Pałucha-Poniewiera, Andrzej Pilc
Oct 21, 2016·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Rong-Jian LiuRonald S Duman
Nov 22, 2017·Molecular Psychiatry·J CastelloH Rebholz
May 2, 2019·The American Journal of Psychiatry·Michael Wang, Adam Kaplin
Feb 25, 2020·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Chadi G AbdallahJohn H Krystal
Oct 2, 2019·Current Neuropharmacology·Kaipuzha Venu AthiraSumana Chakravarty
Aug 8, 2018·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Jeffrey J LiuLee-Yuan Liu-Chen
Feb 2, 2019·Oncogene·Yao JiangPengda Liu
Mar 22, 2019·Molecular Psychiatry·Ronald S DumanBrendan Hare
Aug 28, 2017·Current Psychiatry Reports·John H KrystalRonald S Duman
Jun 23, 2018·Science·Jeffrey J LiuMatthias Mann
Jun 15, 2017·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Maged M Harraz, Solomon H Snyder
Jan 17, 2019·Cell and Tissue Research·Samia R L JocaGregers Wegener
Dec 19, 2018·Proceedings of the National Academy of Sciences of the United States of America·Kenichi FukumotoRonald S Duman
Feb 6, 2019·Advances in Pharmacological Sciences·Mervin Chávez-CastilloJoselyn Rojas-Quintero
Sep 2, 2020·European Journal of Pharmacology·Maciej KorczakMagdalena Bujalska-Zadrożny
Jul 28, 2019·European Journal of Pharmacology·Agata Nowacka, Malgorzata Borczyk
Feb 12, 2021·Neuropsychiatric Disease and Treatment·Xiaomei ZhongWeiru Zhang
Jun 13, 2021·Progress in Neurobiology·Shuai ZhangXiaofeng Jia
Jul 31, 2021·World Journal of Psychiatry·Adejoke Yetunde Onaolapo, Olakunle James Onaolapo
Oct 4, 2018·Journal of Agricultural and Food Chemistry·Adi ShpaizerOren Tirosh

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.